These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 29934218

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
    Lei M, Feng H, Bai E, Zhou H, Wang J, Qin Y, Zhang H, Wang X, Liu Z, Hai O, Liu J, Zhu Y.
    Org Biomol Chem; 2019 Jan 16; 17(3):683-691. PubMed ID: 30601533
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma.
    Wang X, Zhang W, Wen T, Miao H, Hu W, Liu H, Lei M, Zhu Y.
    Eur J Med Chem; 2023 Mar 15; 250():115187. PubMed ID: 36806958
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Ge Y, Li A, Wu J, Feng H, Wang L, Liu H, Xu Y, Xu Q, Zhao L, Li Y.
    Eur J Med Chem; 2017 Mar 10; 128():180-191. PubMed ID: 28182990
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
    Shi J, Lei M, Wu W, Feng H, Wang J, Chen S, Zhu Y, Hu S, Liu Z, Jiang C.
    Bioorg Med Chem Lett; 2016 Apr 15; 26(8):1958-62. PubMed ID: 26965867
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
    Sun Q, Zhou T, Xi D, Li X, Lü Z, Xu F, Wang C, Niu Y, Xu P.
    Eur J Med Chem; 2020 Apr 15; 192():112160. PubMed ID: 32146375
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
    Zhang J, Shen L, Wang J, Luo P, Hu Y.
    Med Chem; 2014 Apr 15; 10(1):38-45. PubMed ID: 23676009
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Design, Synthesis, and Biological Activity of Isosyringolin A.
    Kitahata S, Chiba T, Yoshida T, Ri M, Iida S, Matsuda A, Ichikawa S.
    Org Lett; 2016 May 06; 18(9):2312-5. PubMed ID: 27123978
    [Abstract] [Full Text] [Related]

  • 16. Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids.
    Zhu Y, Wu G, Zhu X, Ma Y, Zhao X, Li Y, Yuan Y, Yang J, Yu S, Shao F, Lei M.
    J Med Chem; 2010 Dec 23; 53(24):8619-26. PubMed ID: 21077681
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
    Niroula D, Hallada LP, Le Chapelain C, Ganegamage SK, Dotson D, Rogelj S, Groll M, Tello-Aburto R.
    Eur J Med Chem; 2018 Sep 05; 157():962-977. PubMed ID: 30165344
    [Abstract] [Full Text] [Related]

  • 18. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K, Troiano V, Ettari R, Pinto A, Micale N, Di Giovanni C, Cerchia C, Schirmeister T, Novellino E, Lavecchia A, Zappalà M, Grasso S.
    ChemMedChem; 2014 Aug 05; 9(8):1801-16. PubMed ID: 24891205
    [Abstract] [Full Text] [Related]

  • 19. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
    Li S, Zhao C, Zhang G, Xu Q, Liu Q, Zhao W, James Chou C, Zhang Y.
    Bioorg Chem; 2021 Nov 05; 116():105278. PubMed ID: 34474303
    [Abstract] [Full Text] [Related]

  • 20. Urea-containing peptide boronic acids as potent proteasome inhibitors.
    Han LQ, Yuan X, Wu XY, Li RD, Xu B, Cheng Q, Liu ZM, Zhou TY, An HY, Wang X, Cheng TM, Ge ZM, Cui JR, Li RT.
    Eur J Med Chem; 2017 Jan 05; 125():925-939. PubMed ID: 27769033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.